Skip to main content
SpringerLink
Log in

A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Purpose: Pharmacological studies of gemcitabine (2′,2′-difluorodeoxycytidine) have shown that increased levels of the active triphosphate metabolite are achieved by prolonging infusion time while holding the dose rate constant. The primary aim of this study was to determine the maximum tolerated dose (MTD) of gemcitabine administered as a fixed rate infusion (10 mg/m2/min) on a weekly schedule in patients with untreated non-hematologic malignancies.

Patients and methods: Twenty-seven patients (21 pancreatic adenocarcinoma, 3 hepatoma, 1 neuroendocrine tumor, and 2 adenocarcinoma of unknown primary) were enrolled in this open-label, non-randomized study. Three different entry dose levels (1200 mg/m2, 1500 mg/m2 and 1800 mg/m2) were evaluated for gemcitabine administered on days 1, 8, and 15 of a 28-day cycle.

Results: The MTD was defined as 1500 mg/m2 with granulocytopenia and thrombocytopenia being dose-limiting. There were no non-hematological dose limiting toxicities. The maximum WHO grade 3 or 4 toxicities for hemoglobin, leukocytes, neutrophils, and platelets for all doses of gemcitabine administered were 11.5%, 30.8%, 57.7%, and 26.9%, respectively. Non-hematologic toxicities included nausea, vomiting and fever. Four patients were withdrawn from the study for non-hematological toxicities: pneumonitis, ascites, disabling fatigue, and an acute myocardial infarction. Two of these events were severe (pneumonitis and myocardial infarction) but these may not be related to drug administration.

Conclusion: Gemcitabine administered at a rate of 10 mg/m2/min was tolerated up to 1500 mg/m2 in patients with previously untreated non-hematologic malignancies. Myelosuppression seen in this study is more severe than anticipated based on previous reports of bolus administration of similar doses of gemcitabine. This supports earlier studies suggesting that prolonged duration of infusion increases the intracellular accumulation of active metabolites of gemcitabine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Rindey GB: Evaluation of the antitumor activity of gemcitabine (2′,2′-Difluoro-2′-deoxycytidine). Cancer Res 40:4417–4422, 1990

    Google Scholar 

  2. Grindey GB: Current status of cancer drug development: Failure or limited success? Cancer Cells 2:163–171, 1990

    Google Scholar 

  3. Anderson H, Lund B, Back F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1821–1826, 1994

    Google Scholar 

  4. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg T: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study. J Clin Oncol 12:1535–1540, 1994

    Google Scholar 

  5. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29–34, 1994

    Google Scholar 

  6. Pollera CF, Ceribelli A, Crecco M, Calabreso F: Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182–184, 1994

    Google Scholar 

  7. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Nat Cancer Inst 86:1530–1533, 1994

    Google Scholar 

  8. Catimel G, Vermorken JB, Clavel M, Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H, Kaye SB: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5:543–647, 1994

    Google Scholar 

  9. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731–2736, 1995

    Google Scholar 

  10. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V: Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3–10, 1995

    Google Scholar 

  11. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W: Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823–6826, 1990

    Google Scholar 

  12. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498, 1991

    Google Scholar 

  13. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W: Gemcitabine in leukemia: A phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406–413, 1992

    Google Scholar 

  14. Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabine in advanced or metastatic solid tumors. Invest New Drugs 12:111–119, 1994

    Google Scholar 

  15. O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee WG, Tarassoff PG, VonHoff DD: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days [letter]. Eur J Cancer 30A:417–418, 1994

    Google Scholar 

  16. Poplin EAD, Corbett T, Flaherty L, Tarassoff P, Redman BG, Valdivieso M, Baker L: Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study. Invest New Drugs 10:165–170, 1992

    Google Scholar 

  17. Clavel M, Guastella J, Peters G: Phase I study of LY-188011, 2′,2′-difluorodeoxycytidine. Invest New Drugs 7:379, 1989

    Google Scholar 

  18. Fossella FV, Lippman SM, Tarassoff P, Shin DM, Calayag M, Lee JS, Murphy WK, Perez-Soler R, Glisson BS, Hong WK: Phase I/II study of gemcitabine: An active agent for non-small cell lung cancer (NSCLC). Proc ASCO 14:371, 1995 (abstr 1144)

    Google Scholar 

  19. Tonato M, Mosconi AM, Martin C: Safety profile of gemcitabine. Anti-Cancer Drugs 6:27–32, 1995

    Google Scholar 

  20. Moore M, Andersen J, Burrls H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R, Storniolo A, VonHoff D: A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer. Proc ASCO 14:199, 1995 (abstr 473)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA

    Randall Brand, Mary Capadano & Margaret Tempero

Authors
  1. Randall Brand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary Capadano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margaret Tempero
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brand, R., Capadano, M. & Tempero, M. A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15, 331–341 (1997). https://doi.org/10.1023/A:1005981317532

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005981317532

Search

Navigation